Normunity, Inc. is a biotechnology firm that is developing a pioneering category of precise immuno-oncology medications known as immune normalizers. These medications are designed to target innovative mechanisms that unleash the body's natural immune response against cancer. Through a collaborative relationship with Dr. Lieping Chen's laboratory at Yale School of Medicine, Normunity is focusing on uncovering newly identified mechanisms of immune system disruption in cancer, leveraging exclusive discovery platforms to illuminate the intricate interactions between human cancer and the immune system.